New York, N.Y (USA) and Paris (France), April 11, 2019 – Zionexa, a radiopharmaceutical company specialized in the development and commercialization of innovative molecular imaging companion diagnostics (CDx) for targeted therapies in oncology, announced today that it has completed a second capital raise of $5 Million via two French investment funds, iXO Private Equity and SofiMac, as well as Denos, its majority shareholder.

This funding has been realized in line with Zionexa’s initial 2018 plan in order to raise a total of $10 Million with the first 12 months in order to register with the FDA (Food and Drug Administration), its first pipeline molecule, EstroTep, an innovative biomarker for targeted in-vivo diagnostic of metastatic breast cancer.

These additional funds will also enable Zionexa to further develop its pipeline of other innovative molecules, notably with the launch of multicentric Phase III clinical trials in Europe that Zionexa will sponsor. A more significant third fundraising is planned within the next 12 months, to finance the commercial launches of EstroTep, in the U.S. and France.

Bernard Landes, CEO at Zionexa, comments: “This second fundraising will allow us to accelerate the launch of EstroTep and further develop our pipeline of targeted biomarkers for early and specific cancer diagnostic. Today, many patients follow heavy and often inadequate treatments. Our objective is to give clinicians access to innovative companion diagnostics tracers, in order for them to use these tracers in real life and contribute to improve the quality of their patient’s pathway. EstroTep, our first innovative companion diagnostic tracer has demonstrated its relevance in multiple clinical trials around the world.”

Baptiste Martin-Wurmser, Investment Director at IXO Private Equity adds:” Medical Imaging is a priority investment area for IXO Private Equity. Zionexa, specialized in molecular imaging, successfully develops new molecules that meet various needs: it helps clinicians better monitor patients’ disease and treatments, notably by evaluating their effectiveness. This has been key in our decision to invest in such an early stage project as well as the fact that we already knew the management team and its quality.”

Cécile Thébault, Associate Investments Director at Sofimac, further comments:” We are very glad to support this company which has key advantages in a high potential sector, especially in the U.S. Zionexa has an international and complementary team of experts, that bring a comprehensive know-how to the company, in terms of development, regulatory and market access of radiopharmaceuticals. Zionexa’s, ambitious pipeline, includes a first very promising molecule, EstroTep, that might be commercialized within 12 months.”


About Zionexa – www.zionexa.com
Zionexa is an international and innovative company developing and commercializing molecular imaging solutions, companion diagnostics (CDx) for targeted therapies in oncology, to improve patients’ pathway and provide them a better quality of life.


About IXO Private Equity – www.ixope.fr
Founded in 2003, iXO Private Equity is the leading independent regional private-equity player in France. With assets under management of more than € 750 million, the management company mainly invests in growth capital and transmissions operations. iXO Private Equity invests from € 2 to € 20 million in SMEs based in the Great South of France.


About Sofimac Régions – www. sofimac-im.com
SofiMac Regions is an independent financial company certified by AMF (French Financial Market Authority) dedicated to investments in growth capital / transmission, proximity risk capital and turnaround. Based in France in Paris, Clermont-Ferrand, Orléans, Lyon, Limoges, Aix-en-Provence, Caen and Rennes, Sofimac regions benefits from a public and private subscribers’ network. Sofimac Regions currently manages 450 million euros of assets, through 17 funds, invested in more than 200 companies.